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ABSTRACT:
Every being wants to live a healthy life. The increase in the discovery and development of medicines is the provoking 
demand of mankind to meet with the increasing and spreading illness of the society. Pharmaceutical Sciences have proved its 
worth to meet with the emerging problems with thorough challenges.The concept of probiosis, prebiosis and symbiosis have 
been recently emerged and being implemented  in pharmaceutics to develop, design and delivery of probiotic drugs which 
can be administered orally as other medicines with its efficient efficacy and least jeopardy.However with the undergoing 
trends of its designing and discovery, the emphasis has been focused on to its bimolecular mode of action. The present 
review work would also emphasize the pros and cons of the probiotic food supplements with the necessity for the invention 
of preceding probiotic drugs which would rapidly pounce, quell and substitute the use of probiotic foods. The idea of this 
probiotic drug designing will be salutary to the society and would also meet with the cost.
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1. INTRODUCTION:
     A Probiotic term derives from the combined Greek/Latin word “pro” and “bios”, meaning for life. The concept of 
probiotic was probably firstly introduced by the Russian Nobel laureate Elie Metchnikoff in 1907 “The Prolongation of Life: 
Optimistic Studies” where he proposed the idea that ingesting microbes could have beneficial effects for human beings, 
especially to treat digestive diseases.” [1].
     The term “probiotic” was firstly used in 1965, by Lilly and Stillwell, to describe substances secreted by one organism 
which stimulates the growth of another.
Probiotic is a defined as “live microorganisms that beneficially affect the host’s health by improving its microbial balance” 
[2]. 
     More recently, probiotics have been defined as “live microorganisms that, when administered in adequate amounts, 
confer a health benefit on the host” [3]
      The objective of present review work is to make the Indian society and particularly the poor mass aware about the less 
recognized, affordable but the most beneficial ways of improving their health by probiotic formulation. 
1.1 Gut Ecology
       The GIT of the human body is a complex ecosystem with a diverse and concentrated microbial population that mediates 
numerous interactions with the chemical environment, such as digestion, adhesion and colonization in the GIT.
      The human body consists of 10 Crore cells but we harbor 100 Crore bacteria in different parts of body [4]
Microorganisms are present all over the body except heart and brain.
Human Body is comprised of 1013 cells
      Our Digestive system contains 1014 Bacterial cells. 10 Times more Bacteria than Human Cells. More than 500 different 
bacterial species inhabit the human gut. Some of them are beneficial and some of them are harmful. Normal intestinal flora 
is a complex collection and balance of microorganisms that normally inhabit the G.I. tract.
     Varying numbers of bacteria are found throughout the GIT, ranging from 102-103 cfu/ g in the stomach contents; 104  to 
105 cfu/g in the jejunum, up to 107 cfu/g in the terminal ileum and approximately 109 to 1012 cfu/g in the distal colon 
contents. [5]
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Figure 1.  Key physiologic and microbiological features of the gut and relative concentrations of microflora in GIT.
1.2 Role of Microflora in the GIT [6]
      The normal flora which colonizes the GI tract exerts several functions:
 synthesizing and excreting vitamins in excess of their own needs, which can be absorbed as nutrients by their hosts 
(enteric bacteria secrete Vitamin K and Vitamin B12, and lactic acid bacteria produce certain B-vitamins)
 preventing the pathogens colonization by competing for attachment sites or essential nutrients
 being likely to produce substances which inhibit or kill non indigenous species
 stimulating the development of certain tissues, i.e., the caecum and certain lymphatic tissues in the GI tract
 stimulating the production of natural antibodies
 producing a variety of substances ranging from relatively non-specific fatty acids and peroxides to highly specific 
bacteriocins which inhibit or kill other bacteria
1.3 Mechanisms of Action of Probiotics [7-13]
1.3.1 Antimicrobial Effects of Probiotics.
 Modify microflora to suppress pathogens.
 Secrete antibacterial substances.
Probiotic bacteria produce a variety of substances that are inhibitory to both gram-positive and gram-negative 
bacteria. These include organic acids, hydrogen peroxide and bacteriocins. These compounds may reduce not only 
the number of viable pathogenic organisms but may also affect bacterial metabolism and toxin production. This 
occurs through reduction of luminal pH through the production of volatile short-chain fatty acids, mainly acetates, 
propionates and butyrates. And of course, through production of lactic acid (Bifidobacterium, Lactobacillus, 
Streptococcus), leading to a reduction in colonic pH
 Compete with pathogens to prevent their adhesion to the intestine
 Compete for nutrients necessary for pathogen survive
 Antitoxin effect
1.3.2 Effect of Probiotics on the Intestinal Epithelium.
 Promote tight contact between epithelial cells forming a functional barrier.
 Reducing the secretory and inflammatory consequences of bacterial infection.
 Enhancing the production of defensive molecules such as mucins.
1.3.3 Immune Effects of Probiotics
 Probiotics as vehicles to deliver anti-inflammatory molecules to the Intestine.
 Enhance signaling in host cells to reduce inflammatory response.
 Switch in immune response to reduce allergy.
 Reduce the production of inflammatory substances.
1.4 Characteristics of probiotic [14, 15]
      The probiotic bacteria selected should have the following main characteristics: 
 They should have “non-pathogenic’ activity
 They should be “resistant to bile salts” and gastric acids
 They should have the “desired technological and organoleptic properties”
 They should have “biological efficiency” on humans, including ‘adhesion to epithelial cells’ in the intestine
 They should interact with “enteropathogenic” bacteria
 They should be able to “colonize” in the gut
 They should be able to “stimulate the immune system”.
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1.5 Taxonomy of probiotic
Table 1. Commonly used probiotics species for human use
Lactobacillus Bifidobacterium Streptococcus Enterococcus
L.acidophilus                    
L.rhamnosus
B.bifidum  ,              
B.breve
S.cremoris E.faecium
L.brevis                              
L.gallinarum
B.bifidus,                 
B.adolescentis
S.diacetylactis E.faecalis
L.bulgaricus                      
L.plantarum
B.longum S.intermedus
L.casei                               
L. GG
B.lactis S.salivarius
L. fermentum                     
L.reuteri
B.infantis
2. IMPORTANT PROPERTIES OF PROBIOTICS
      The most important properties for current and future probiotics include the acid and bile tolerance, adherence to human 
intestinal mucosa, temporary colonization of the human gastrointestinal tract, production of antimicrobial substances and 
inhibition of pathogen growth [17]
Table 2. Essential properties of probiotics
Probiotics strain characteristics Functional properties
Human origin, if intended for human use
Species-dependent health effects and maintained 
viability; applicability to functional and clinical foods
Acid and bile stability
Survival in the intestine, maintaining adhesiveness and 
other properties
Adherence to human intestinal cells and  intestinal 
mucus glycoproteins (mucin)
Immune modulation, competitive exclusion of 
pathogens
Competitive exclusion and colonization of  the 
human intestinal tract 
Multiplication in the intestinal tract, competitive 
exclusion of pathogens, stimulation of beneficial micro 
flora, immune modulation by contact with gut 
associated lymphoid tissue
Production of antimicrobial substances
Pathogen inactivation in the intestine, normalization of 
gut flora
Antagonism against cariogenic and pathogenic 
bacteria
Pathogen exclusion, prevention of pathogen adhesion, 
normalization of gut flora, normalization of gut micro 
flora
Safety in food and clinical use
Accurate strain identification (genus, species, strain) 
and characterization,
documented safety
Clinically validated and documented health  effects
Dose response data for minimum effective dosage in 
different products
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Table 2. Important Properties of probiotics [18]
3. FORMULATION ASPECTS OF PROBIOTIC
        Formulation development of probiotic begins with the product design and moves forward through clinical studies to the 
development of the commercial manufacturing process. Important clinical studies for the clinical assessment of probiotic are 
shown in the table 3. [19]
Type of property studied Clinical factor to be evaluated
Intrinsic properties of lactic acid bacteria
Adhesion factors, antibiotic resistance, existence of 
plasmids and plasmid transfer potential, enzyme profile
Metabolic products
Concentrations, antimicrobial effects on intestinal micro 
flora, safety
Mucosal effects
Adhesion to intestinal cells and mucus, intestinal mucus 
degradation, stabilisation effect on intestinal permeability
Dose response effects Dose response studies by oral administration in volunteers
Clinical assessment
potential for side-effects, disease specific effects, nutritional 
studies, intestinal micro flora effects
Epidemiological studies
Surveillance of large populations following introduction of 
new strains and products for both health effects and safety
Table 3. Important clinical studies for the clinical assessment of probiotic
      The goal of product design is a fully validated, good manufacturing practice (GMP)–compliant process that will ensure 
the continued and consistent quality of the final product for its intended use. 
      The manufacturing process should be designed and adjusted as needed to ensure the safety, purity, and stability of the 
live microorganism in its final dosage form. 
Safe and effective use of a live biotherapeutic biological drug depends on consistent manufacture and release according to 
valid specifications.
       Product design for probiotics starts with the selection of a strain of bacteria or yeast that has characteristics thought to be 
associated with healthy functioning of human body systems.
3.1 Selection of production strains
       Microorganisms chosen for the production of probiotics are subject to a careful selection process. [20] They are isolated 
from their natural environment and subjected to specific studies. 
      First, microbiological tests and selection procedures are carried out to evaluate their suitability. Their fermentation 
profiles are determined revealing which substrates are fermented to which metabolites, For example: API assay for the 
fermentation of sugar to lactic acid. Comprehensive and accurate characterisation of the microorganism is also necessary. 
Amongst others, the genetic fingerprint, which is determined by molecular biological tests such as DNA analysis, is used for 
this purpose. In addition, the behaviour of the microorganism in the animal is studied, i.e. whether it survives the intestinal 
passage, how long it remains in the intestine and how it regulates the intestinal ecosystem. All this is the basis for an 
additional selection criterion – the efficacy in the animal. In addition, safety aspects also play a decisive role. [21]
      For production purposes it is important that the microorganism is capable of effective large-scale proliferation and that it 
remains genetically stable.
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Strain Identification by Phenotypic and Genotypic Methods
Flow Diagram of Guidelines for the Evaluation of Probiotics is given in the figure 2
3.2 Production
       Probiotics are manufactured by fermentation which is a biological procedure under the controlled supply of nutrients. 
All raw materials used are subject to strict quality controls. The sterile fermentation vessel is inoculated with the master seed 
culture either directly or indirectly after a pre-culture stage with all important parameters of production being monitored 
continuously. This is followed by concentration, also called cell harvesting. Special drying stages and, if necessary, the 
addition of specific stabilisers, complete the manufacturing process. 
        In some products, the microorganisms are protected by microcapsules or microspheres for better stability.  [22]
       A schematic illustration of the manufacturing process is shown in Figure 3
                  
      The active ingredient of a live biotherapeutic is the harvested and concentrated live organism. This is formulated into a 
dosage form that is convenient for use, ensures accurate dosage content, and ensures the quality of the active ingredient. 
Figure 3. Manufacturing process of Probiotic formulation
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       Usually, a concentrated harvest is adjusted by dilution, or a dried preparation is blended with other dry ingredients, such 
as stabilizers or fillers. Liquid preparations to be frozen may be stabilized with cryoprotectants. 
      Uniformity of the dosage form is ensured by monitoring of weights and volume during the filling of vials, capsules, or 
sachets or during compression into tablets. Tablets and capsules may be enteric coated to ensure passage through the 
stomach and dissolution in the intestine. Powdered product may be supplied with prepackaged buffered reconstituting 
solutions. [23]
3.3 Probiotic product Specification 
       Specifications are acceptance criteria to which active ingredients and drug product must conform before they can be 
released as products for human use. Acceptance criteria are dependent on the methods used to obtain the results. 
Specifications should be established for critical materials used in the manufacture of human drugs and biologics, for 
intermediates, and for the final products. Specifications for product release are chosen to confirm the product quality, rather 
than to characterize the product.
Table 4. Main currently used in vitro tests for the study of probiotic strains
 Resistance to gastric acidity
 Bile acid resistance
 Adherence to mucus and/or human epithelial cells and cell lines
 Antimicrobial activity against potentially pathogenic bacteria
 Ability to reduce pathogen adhesion to surfaces
 Bile salt hydrolase activity
 Resistance to spermicides (applicable to probiotics for vaginal use)
Table 4. Main currently used in vitro tests for the study of probiotic strains
3.4 Quality assurance and regularity issues of probiotics 
       The harvested live organism is the active pharmaceutical ingredient. Before formulation, the active pharmaceutical 
ingredient is tested and released against acceptance criteria that ensure the quality of the final product. [24]
       Specific identity testing is performed to confirm the strain and its critical characteristics. For recombinant strains, 
products of transgene expression should be verified. 
      Microbiological purity should be assessed for the purified active pharmaceutical ingredient and after high-risk 
manufacturing steps that might allow extraneous contamination. Testing methods, such as the may be used to ensure 
freedom from extraneous organisms. [25] Purity testing at the stage of the active pharmaceutical ingredient is more sensitive 
than is testing after dilution to prepare the final dosage form. Test methods are selected to detect the most likely 
contaminants. Although sterility of the live product and intermediates is not claimed, extraneous bioburden should be 
controlled by GMP and should be monitored at significant points in the manufacturing process. [26]
        Finally, an accurate quantity of viable organisms is determined using sample dilution and colony counts. Yield of the 
active ingredient should be measured as colony-forming units per product unit. This value guides formulation and is a useful 
monitor of process consistency.
       The regulations for Probiotic list the product qualities that must be evaluated for each lot of product: potency, general 
safety, sterility, purity, and identity. [27] For some qualities, the methodology is also specified. 
3.4.1 Potency:
         Potency is the specific ability or capacity of the product to affect a given result. Potency is defined as a quantitative 
measure of an attribute linked to relevant biological properties. [28] The simplest measure of potency for a live 
biotherapeutic is colony-forming units per dose unit. The accuracy of the measure of colony-forming units will be 
determined by the sample size, homogeneity of the sample, and number of replicate plates per diluted sample. If an end 
product of the microbe is associated with or predictive of therapeutic activity, then an assay of the end product is also 
appropriate. A semiquantitative assay of an expressed product may be sufficient when combined with measurement of 
colony-forming units or another quantitative biochemical assay. Potency is often measured against a reference material or a 
specially prepared batch of active pharmaceutical ingredient. 
3.4.2 Viability
         Many scientists insist on the viability of the microorganisms used as probiotics, several studies have shown that non-
viable probiotics, too, can attach to the intestinal wall and reduce duration of diarrheal diseases [29]
        Studies examining probiotics immunological attributes have indicated that when living cells were given to patients, it 
led to a considerable increase in the number of cells that secrete IgA. [30]
        The viability of the probiotic cells is essential for the probiotic antigens to be taken up through the Peyer’s patch, and 
also to adhere to the M-cells within the intestine [31-33]
Probiotic encapsulation technology used to ensure the probiotic viability which can sometimes solve this problem. [34]
3.4.3 Survival within the GI tract
         In order for probiotics to have beneficial health effects, they must be able to travel through the upper gastro-intestinal 
(GI) tract intact. They must pass through the GI safely so as to reach the location they are to colonize. 
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         In order for the colonization to happen, probiotic must adhere to intestine’s epithelial and mucosal cells. This affects 
the length of time the bacteria stays within the intestine. Also, it has an impact on the functional performance of the bacteria. 
        The bacteria are strained by a number of stress factors while moving forward in the intestine. One such factor is the 
extremely low acidity (pH 1.5-3) of the stomach. The lowest acidity in which LAB can survive is 3.0, considerably higher 
than the acidity in stomach [35].
The extremely high pH environment in the stomach is a crucial parameter in choosing LAB strains. This harsh condition has 
a powerful impact on the viability of bacteria in the stomach. Olejnik et al. demonstrated that yoghurt’s pH reduced viable L. 
casei cells, for 13 days, by 2 log-cycles, and when the pH reached 6.5, more than 30 days. These figures were 3 and 30 days 
at pH 4 and 6.6, respectively, for L.acidophilus [35].
3.4.4 Adhesion
         It has been suggested that probiotic bacteria’s attachment to the intestine’s wall and their colonization of the gastro-
intestinal tract is a vital precondition for their survival and functioning. Strains of probiotic bacteria with adherent properties 
are likely to stay longer in the intestine. They, thus, have better chances for manifesting immunological and metabolic 
effects, compared to the strains with no adhesion properties. [36] The bacteria’s adhesion property causes them to interact 
with the mucosal surface and makes contact with gut associated lymphoid tissue (GALT) possible. It also plays a role in 
intestinal and systemic immune effects. Only probiotics with adherent properties are believed to stabilize the intestinal 
mucosal barrier and to be instrumental in inducing the immune effects. [37] Adhesion may also administer routes of 
exclusion of harmful bacteria and keep them away from the epithelium. Various strains of probiotic bacteria possess 
different adhesive properties. It could be suggested that powerful capability for adhesion may raise the risk of infection in 
the individual. Certain strains of probiotics which are poorly adhering in vivo or in vitro still can show positive effects in the 
hosts.
3.4.5 Safety
         The general safety test method specifies doses given by intraperitoneal injection to mice and guinea pigs observed for 
adverse effects for 7 days. The general safety test is intended to detect extraneous toxic contaminants in the final product.
[38,39] It is not intended as a test of inherent product toxicity and must be modified for products that are toxic by nature 
(e.g., live organisms given parenterally in high doses).[40] A regulatory exemption from the general safety test may be 
requested, provided that GMP and quality controls are in place. [41, 42]
In short, safety issues concerning probiotics cover the following attributes: [43, 44]
Figure 4. Safety aspect of probiotics
3.4.6 Sterility
          Sterility testing is usually not appropriate for live biotherapeutics. A modification of the test method might be 
designed with consideration of the special characteristics of the organism, such as generation time or anaerobic growth 
requirements. Sterility testing may be waived for products that are administered orally [45]
3.4.7 Purity
         Purity testing is repeated for the dosage form, to rule out extraneous contamination during formulation and finishing 
steps. For certain dosage forms, dissolution or resistances to gastric acid are appropriate tests to ensure that the active 
ingredient will reach its most effective site for activity. [24]
3.4.8 Identity
        For final products that are dried or freeze-dried, the moisture content is a critical parameter that can affect the viable 
cell count and product quality during its shelf life. Moisture content is measured for any product prepared in a dried form. 
Identity testing should differentiate the product from similar products produced in the same manufacturing areas. A 
combination of phenotypic and genotypic tests should be used. [45]
3.4.9 Stability
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          Stability studies are performed to ensure that the product remains safe and effective for its intended use throughout its 
specified shelf life. The dosage form should be tested in the actual container or closure system intended for marketing and 
should be stored at the recommended temperature. 
The FDA will review data that support the recommended usage and administration instructions in the package insert as 
follows. [47, 48]
1. If a powdered drug product is supplied with a liquid for reconstitution, the stability of the reconstituted product 
should be studied. 
2. If a powdered or liquid product is combined with a consumer-supplied matrix, support for the recommendation must 
be presented as stability data. Limits on the kinds of diluents or appropriate foods should be stated in the package 
insert. 
3. Consumers should be instructed on the limits of storage time after reconstitution or combination with any 
recommended diluent or matrix. 
A stability protocol defines the kinds of testing to be performed and a schedule for each test. Most release testing is included, 
but every test may not be required at every time point. The kinds of assays to include are those that test potency, purity, 
moisture, and bioburden.         
4. LABELING GUIDELINES PROBIOTIC FORMULATION [49]
    The probiotic formulation label should contain the following information:
 Genus, species and strain designation
 Functionality of the strains(s)
 Minimum viable numbers of each probiotic strain (CFU/g) at the end of the shelf-life.
 The suggested serving size must deliver the effective dose of probiotic related to the health claim(s)
 Total servings per container
 Health claim(s) if any (substantiated with scientific research)
 Storage condition requirements
 Nutrition/Supplement facts
 Manufacturer's name and address
 Manufacturer's lot number and expiration date.
5. FUTURE PROSPECTIVE 
    The probiotic concept is today widely spread in the scientific and industrial fields. However, further scientific input is 
required. Important target research areas, including GI-tract diagnostics and immunology, methodology, biomarkers, and 
functionality, will lead to tools and scientifically sound methods for well-designed informative human studies. Controlled 
human studies are essential for the success of probiotic functional foods, and they should be tailored for specific population 
groups such as the paediatric and elderly. Future research on probiotic bacteria will centre on selecting new and more 
specific strains for the well being of the host (age groups, healthy populations, disease specific).
The future scientific and technological research trends will be:
 To study the mechanisms of action of probiotics in the GI-tract, and develop diagnostic tools and biomarkers for 
their assessment.
 Studies on gut microbiota interactions with metabolic phenotypes -(so called functional metagenomics)
 Understanding of microbiota diversity on a population level and across various cultural and ethnic groups.
 To standardize the microbiota analysis methodology, sample collection, storage, analysis methods
 Correlating microbiota composition with disease risk, require large prospective epidemiological studies.
 To examine the effects of probiotics on GI-diseases, GI-infections, and allergies.
 To ensure the stability and viability of probiotic products by developing feasible technologies (e.g. process and 
material development for microencapsulation).
 To develop technology for pharmaceutical applications of novel or artificial probiotic.
 To evaluate the role of probiotics in healthy consumer groups and to address consumer aspects.
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